NAME	MARKET CAP	FORWARD PE RATIO
Novo Nordisk A/S (NVO)	$217.21B	N/A
Amgen Inc. (AMGN)vs ›	$196.25B	16.45
Thermo Fisher Scientific Inc. (TMO)vs ›	$194.99B	20.52
Gilead Sciences, Inc. (GILD)vs ›	$167.41B	N/A
Abbott Laboratories (ABT)vs ›	$164.43B	17.39
AstraZeneca PLC (AZN)vs ›	$276.82B	18.45
Intuitive Surgical, Inc. (ISRG)vs ›	$145.76B	39.74
Danaher Corporation (DHR)vs ›	$138.71B	22.58
Pfizer Inc. (PFE)vs ›	$138.21B	8.14
CVS Health Corp. (CVS)vs ›	$131.18B	14.08

Trailing vs Forward

Trailing P/E

11.4

reported TTM EPS

Forward P/E

N/A

consensus next-FY EPS

The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $21.56 implies +404.9% EPS growth vs the reported trailing $4.27.

Forward P/E by Fiscal Year

View All Analyst Estimates

At today's $48.88 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.

Fiscal year end	Consensus EPS	Estimate range	Analysts	Implied P/E
2026-12-31	$21.56	$19.58 – $23.66	7	2.3x
2027-12-31	$21.54	$20.42 – $24.37	7	2.3x
2028-12-31	$23.27	$21.05 – $26.28	5	2.1x

Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.

Forward PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

About Novo Nordisk A/S

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Bagsvaerd, CR

77,406 employees

www.novonordisk.com

Healthcare / Drug Manufacturers - General